EUCTR2019-003766-41-NL进行中（未招募）1 期
The effect of Voxelotor on Cerebral Perfusion and Oxygenation (Coverage Study) - COVERAGE Study (ESR-C005)
Amsterdam UMC-AMC0 个研究点目标入组 20 人开始时间: 2020年7月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Documented SCD genotype (HbSS, HbSC, HbS-ß thalassemia or other sickle cell syndrome variants) which may be based on history of laboratory testing or must be confirmed by laboratory testing during screening.
- •2. Age 18 and above
- •3. Hemoglobin (Hb) =10.5 g/dL
- •4. For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least 90 days prior to participation and with no anticipated need for dose adjustments.
- •5. Participants, who if female and of child bearing potential, are using highly effective methods of contraception from study start to 30 days after the last dose of study drug, and who if male are willing to use barrier methods of contraception, from study start to 30 days after the last dose of study drug.
- •6. Participant has provided documented informed consent or assent (the informed consent form [ICF] must be reviewed and signed by each participant; the participant’s legal representative or legal guardian, and the participant’s assent must be obtained).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. No informed consent has been given
- •2. Contra-indication for MRI or acetazolamide
- •3. Female who is breast feeding or pregnant.
- •4. Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or have received a RBC transfusion for any reason within 90 days before participation.
- •5. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days prior participation.
- •6. Hepatic dysfunction characterized by alanine aminotransferase (ALT) >4 × ULN.
- •7. Participants with clinically significant bacterial, fungal, parasitic or viral infection which require therapy:
- •Participants with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
- •Participants with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive.
- •8. Severe renal dysfunction (estimated glomerular filtration rate <30mL/min).
- •9. History of malignancy within the past 2 years prior to participation requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy).
- •10. History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:
- •Unstable angina pectoris or myocardial infarction or elective coronary intervention.
- •Congestive heart failure requiring hospitalization.
- •Uncontrolled clinically significant arrhythmias.
- •11. Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable).
- •12. Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational agent (or medical device).
- •13. Medical, psychological, or behavioral conditions, which, in the opinion of the investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent.
- •14. Receipt of erythropoietin or other hematopoietic growth factors within 28 days of signing ICF or anticipated need for such agents during the study.
研究者
相似试验
尚未招募
不适用
The Effect of Voxelotor on Cerebral Perfusion and Oxygenation (ESR-C005)Sickle Cell DiseaseNL-OMON26164Academic Medical Center (AMC)20
招募中
3 期
The Effect of Voxelotor on Cerebral Perfusion and Oxygenation (ESR-C005)1003815810005330sickle cell diseaseNL-OMON52775Academisch Medisch Centrum24
已完成
不适用
Cerebral Perfusion and Flow Pulsatility in Patients with Aortic Coarctation * a 7 Tesla MRI Study10010394Aortic coarctationnarrowing of the aorta10007963NL-OMON48005niversitair Medisch Centrum Utrecht50
尚未招募
不适用
Changes in cerebral blood flow due to the involvement of nurses in a remote environment in cognitive rehabilitatioDementiaJPRN-UMIN000041231Osaka Medical College10
尚未招募
不适用
Assessment of the changes in brainâ??s blood flow using a CT scan procedure called perfusion CT imaging before and following temporary and partial resection of skull to reduce brain swelling in large, life threatening brain damage due to occlusion of an artery called middle cerebral artery.CTRI/2020/12/029645Sreekesh P V